Barrett, AJ, Le Blanc, K. Prophylaxis of acute GVHD: manipulate the graft or the environment? Best Practice & Research Clinical Haematology. 2008;21(2):165–76.CrossRefGoogle ScholarPubMed

Wysocki, CA, Panoskaltsis-Mortari, A, Blazar, BR, Serody, JS. Leukocyte migration and graft-versus-host disease. Blood. 2005;105(11):4191–9.Google Scholar

Goker, H, Haznedaroglu, IC, Chao, NJ. Acute graft-vs-host disease: pathobiology and management. Experimental Hematology. 2001;29(3):259–77.Google Scholar

Alousi, AM, Bolanos-Meade, J, Lee, SJ. Graft-versus-host disease: state of the science. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2013;19(1 Suppl):S102–8.Google Scholar

Al-Kadhimi, Z, Gul, Z, Chen, W, Smith, D, Abidi, M, Deol, A, et al. High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(7):979–85.Google Scholar

Sung, AD, Chao, NJ. Acute graft-versus-host disease: are we close to bringing the bench to the bedside? Best Practice & Research Clinical Haematology. 2013;26(3):285–92.CrossRefGoogle Scholar

Ferrara, JL, Levine, JE, Reddy, P, Holler, E. Graft-versus-host disease. Lancet. 2009;373(9674):1550–61.Google Scholar

Ruutu, T, van Biezen, A, Hertenstein, B, Henseler, A, Garderet, L, Passweg, J, et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation. 2012;47(11):1459–64.Google Scholar

Hamad, N, Del Bel, R, Messner, HA, Kim, D, Kuruvilla, J, Lipton, JH, et al. Outcomes of hematopoietic cell transplantation in adult patients with acquired aplastic anemia using intermediate dose alemtuzumab-based conditioning. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(11):1722–8.Google Scholar

Kanda, J, Long, GD, Gasparetto, C, Horwitz, ME, Sullivan, KM, Chute, JP, et al. Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(2):257–63.Google Scholar

Grullich, C, Ziegler, C, Finke, J. Rabbit anti T-lymphocyte globulin induces apoptosis in peripheral blood mononuclear cell compartments and leukemia cells, while hematopoetic stem cells are apoptosis resistant. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2009;15(2):173–82.Google Scholar

Bacigalupo, A, Lamparelli, T, Bruzzi, P, Guidi, S, Alessandrino, PE, di Bartolomeo, P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942–7.Google Scholar

Finke, J, Bethge, WA, Schmoor, C, Ottinger, HD, Stelljes, M, Zander, AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. The Lancet Oncology. 2009;10(9):855–64.Google Scholar

Soiffer, RJ, Lerademacher, J, Ho, V, Kan, F, Artz, A, Champlin, RE, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117(25):6963–70.Google Scholar

Theurich, S, Fischmann, H, Shimabukuro-Vornhagen, A, Chemnitz, JM, Holtick, U, Scheid, C, et al. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. The Cochrane Database of Systematic Reviews. 2012;9:CD009159.Google Scholar

Luznik, L, Bolanos-Meade, J, Zahurak, M, Chen, AR, Smith, BD, Brodsky, R, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010;115(16):3224–30.Google Scholar

Luznik, L, O’Donnell, PV, Symons, HJ, Chen, AR, Leffell, MS, Zahurak, M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2008;14(6):641–50.Google Scholar

Reshef, R, Luger, SM, Hexner, EO, Loren, AW, Frey, NV, Nasta, SD, et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. The New England Journal of Medicine. 2012;367(2):135–45.CrossRefGoogle ScholarPubMed

Ram, R, Storb, R. Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future. Leukemia & Lymphoma. 2013;54(8):1591–601.Google Scholar

Koreth, J, Stevenson, KE, Kim, HT, McDonough, SM, Bindra, B, Armand, P, et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012;30(26):3202–8.CrossRefGoogle ScholarPubMed

Kraut, EH, Neff, JC, Bouroncle, BA, Gochnour, D, Grever, MR. Immunosuppressive effects of pentostatin. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1990;8(5):848–55.CrossRefGoogle ScholarPubMed

Parmar, S, Andersson, BS, Couriel, D, Munsell, MF, Fernandez-Vina, M, Jones, RB, et al. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011;29(3):294–302.CrossRefGoogle ScholarPubMed

Dinarello, CA, Fossati, G, Mascagni, P. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Molecular Medicine. 2011;17(5–6):333–52.CrossRefGoogle Scholar

Choi, SW, Braun, T, Chang, L, Ferrara, JL, Pawarode, A, Magenau, JM, et al. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. The Lancet Oncology. 2014;15(1):87–95.Google Scholar

Zeiser, R, Youssef, S, Baker, J, Kambham, N, Steinman, L, Negrin, RS. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood. 2007;110(13):4588–98.Google Scholar

Hamadani, M, Gibson, LF, Remick, SC, Wen, S, Petros, W, Tse, W, et al. Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013;31(35):4416–23.CrossRefGoogle ScholarPubMed

Pillai, AB, George, TI, Dutt, S, Strober, S. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. Blood. 2009;113(18):4458–67.Google Scholar

Lowsky, R, Takahashi, T, Liu, YP, Dejbakhsh-Jones, S, Grumet, FC, Shizuru, JA, et al. Protective conditioning for acute graft-versus-host disease. The New England Journal of Medicine. 2005;353(13):1321–31.CrossRefGoogle ScholarPubMed

Kohrt, HE, Turnbull, BB, Heydari, K, Shizuru, JA, Laport, GG, Miklos, DB, et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 2009;114(5):1099–109.Google Scholar

Messina, G, Giaccone, L, Festuccia, M, Irrera, G, Scortechini, I, Sorasio, R, et al. Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2012;18(10):1600–7.Google Scholar

Ringden, O, Pihlstedt, P, Markling, L, Aschan, J, Baryd, I, Ljungman, P, et al. Prevention of graft-versus-host disease with T-cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplantation. 1991;7(3):221–6.Google ScholarPubMed

Wagner, JE, Thompson, JS, Carter, SL, Kernan, NA, members of the Unrelated Donor Marrow Transplantation Trial. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet. 2005;366(9487):733–41.CrossRefGoogle Scholar

Pavletic, SZ, Carter, SL, Kernan, NA, Henslee-Downey, J, Mendizabal, AM, Papadopoulos, E, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood. 2005;106(9):3308–13.Google Scholar

Pasquini, MC, Devine, S, Mendizabal, A, Baden, LR, Wingard, JR, Lazarus, HM, et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012;30(26):3194–201.CrossRefGoogle ScholarPubMed

Cutler, C, Logan, B, Nakamura, R, Johnston, L, Choi, S, Porter, D, et al. Tacrolimus/sirolimus versus tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic hematopoietic cell transplantation. Blood. 2014;124(8):1372–7.Google Scholar

Luznik, L, O’Donnell, PV, Fuchs, EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39(6):683–93.Google Scholar

Martin, PJ, Rizzo, JD, Wingard, JR, Ballen, K, Curtin, PT, Cutler, C, et al. First-and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18(8):1150–63.Google Scholar

Ruutu, T, Gratwohl, A, de Witte, T, Afanasyev, B, Apperley, J, Bacigalupo, A, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant. 2014;49(2):168–73Google Scholar

Wolff, D, Ayuk, F, Elmaagacli, A, Bertz, H, Lawitschka, A, Schleuning, M, et al. Current practice in diagnosis and treatment of acute graft-versus-host disease: results from a survey among German-Austrian-Swiss hematopoietic stem cell transplant centers. Biol Blood Marrow Transplant. 2013;19(5):767–76.Google Scholar

Salmasian, H, Rohanizadegan, M, Banihosseini, S, Rahimi Darabad, R, Rabbani-Anari, M, Shakiba, A, Ferrara, JL. Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantation. Cochrane Database Syst Rev. 2010;(1):CD005565.Google Scholar

Alousi, AM, Weisdorf, DJ, Logan, BR, Bolaños-Meade, J, Carter, S, Difronzo, N, et al. Blood and Marrow Transplant Clinical Trials Network. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009;114(3):511–7.Google Scholar

Bolaños-Meade, J, Logan, BR, Alousi, AM, Antin, JH, Barowski, K, Carter, SL, et al. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood. 2014;124(22):3221–7.Google Scholar

Couriel, DR, Saliba, R, de Lima, M, Giralt, S, Andersson, B, Khouri, I, et al. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009;15(12):1555–62.Google Scholar

Gatza, E, Braun, T, Levine, JE, Ferrara, JL, Zhao, S, Wang, T, et al. Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(9):1426–34.CrossRefGoogle ScholarPubMed

Takashima, S, Eto, T, Shiratsuchi, M, Hidaka, M, Mori, Y, Kato, K, et al. The use of oral beclomethasone dipropionate in the treatment of gastrointestinal graft-versus-host disease: the experience of the Fukuoka blood and marrow transplantation (BMT) group. Intern Med. 2014;53(12):1315–20.CrossRefGoogle ScholarPubMed

Bürgler, D, Medinger, M, Passweg, J, Fischmann, A, Bucher, C. Intra-arterial catheter guided steroid administration for the treatment of steroid-refractory intestinal GvHD. Leuk Res. 2014;38(2):184–7.Google Scholar

Milner, LA, Becker, MW, Bernstein, SH, Bruckner, L, Friedberg, JW, Holland, GA, et al. Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease. Am J Hematol. 2011;86(8):712–4.Google Scholar

Feldstein, JV, Bolaños-Meade, J, Anders, VL, Abuav, R. Narrowband ultraviolet B phototherapy for the treatment of steroid-refractory and steroid-dependent acute graft-versus-host disease of the skin. J Am Acad Dermatol. 2011;65(4):733–8.Google Scholar

Hoda, D, Pidala, J, Salgado-Vila, N, Kim, J, Perkins, J, Bookout, R, et al. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant. 2010;45(8):1347–51.Google Scholar

Mielke, S, Lutz, M, Schmidhuber, J, Kapp, M, Ditz, D, Ammer, J, et al. Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: A dual center retrospective analysis. Bone Marrow Transplant. 2014;49(11):1412–8.CrossRefGoogle ScholarPubMed

García-Cadenas, I, Valcárcel, D, Martino, R, Piñana, JL, Novelli, S, Esquirol, A, et al. Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19(3):435–9.Google Scholar

Wang, JZ, Liu, KY, Xu, LP, Liu, DH, Han, W, Chen, H, et al. Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation. Transplant Proc. 2011;43(5):1928–33.Google Scholar

Xhaard, A, Rocha, V, Bueno, B, de Latour, RP, Lenglet, J, Petropoulou, A, et al. Steroid-refractory acute GvHD: lack of long-term improved survival using new generation anticytokine treatment. Biol Blood Marrow Transplant. 2012;18(3):406–13.Google Scholar

Drobyski, WR, Pasquini, M, Kovatovic, K, Palmer, J, Douglas Rizzo, J, Saad, A, et al. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17(12):1862–8.Google Scholar

Meunier, M, Bulabois, CE, Thiebaut-Bertrand, A, Itzykson, R, Carre, M, Carras, S, et al. Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20(9):1451–4.Google Scholar

Khandelwal, P, Lawrence, J, Filipovich, AH, Davies, SM, Bleesing, JJ, Jordan, MB, et al. The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. Pediatr Transplant. 2014;18(1):94–102.CrossRefGoogle ScholarPubMed

Schub, N, Günther, A, Schrauder, A, Claviez, A, Ehlert, C, Gramatzki, M, Repp, R. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transplant. 2011;46(1):143–7.Google Scholar

Abu-Dalle, I, Reljic, T, Nishihori, T, Antar, A, Bazarbachi, A, Djulbegovic, B,et al. Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. Biol Blood Marrow Transplant. 2014;20(11):1677–86.CrossRefGoogle ScholarPubMed

Das-Gupta, E, Dignan, F, Shaw, B, Raj, K, Malladi, R, Gennery, A, et al. Extracorporeal photopheresis for treatment of adults and children with acute GvHD: UK consensus statement and review of published literature. Bone Marrow Transplant. 2014;49(10):1251–8.Google Scholar

Pierelli, L, Perseghin, P, Marchetti, M, Messina, C, Perotti, C, Mazzoni, A, et al.; Società Italiana di Emaferesi and Manipolazione Cellulare (SIdEM); Gruppo Italiano Trapianto Midollo Osseo (GITMO). Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process. Transfusion. 2013;53(10):2340–52.Google Scholar

Jagasia, M, Greinix, H, Robin, M, Das-Gupta, E, Jacobs, R, Savani, BN, et al. Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. Biol Blood Marrow Transplant. 2013;19(7):1129–33.Google Scholar

Rieber, N, Wecker, I, Neri, D, Fuchs, K, Schäfer, I, Brand, A, et al. Extracorporeal photopheresis increases neutrophilic myeloid-derived suppressor cells in patients with GvHD. Bone Marrow Transplant. 2014;49(4):545–52.Google Scholar

Mevorach, D, Zuckerman, T, Reiner, I, Shimoni, A, Samuel, S, Nagler, A, et al. Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial. Biol Blood Marrow Transplant. 2014;20(1):58–65.Google Scholar

Sánchez-Guijo, F, Caballero-Velázquez, T, López-Villar, O, Redondo, A, Parody, R, Martínez, C, et al. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20(10):1580–5.Google Scholar

Introna, M, Lucchini, G, Dander, E, Galimberti, S, Rovelli, A, Balduzzi, A, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant. 2014;20(3):375–81.Google Scholar

Ball, LM, Bernardo, ME, Roelofs, H, van Tol, MJ, Contoli, B, Zwaginga, JJ, et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III–IV acute graft-versus-host disease. Br J Haematol 2013;163(4):501–9.Google Scholar

Schneidawind, D, Pierini, A, Negrin, RS. Regulatory T cells and natural killer T cells for modulation of GvHD following allogeneic hematopoietic cell transplantation. Blood. 2013;122(18):3116–21.Google Scholar

Reddy, P. Targeting deacetylases to improve outcomes after allogeneic bone marrow transplantation. Trans Am Clin Climatol Assoc. 2013;124:152–62.Google Scholar

Marcondes, AM, Li, X, Tabellini, L, Bartenstein, M, Kabacka, J, Sale, GE, et al. Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model. Blood. 2011;118(18):5031–9.Google Scholar

Tawara, I, Sun, Y, Lewis, EC, Toubai, T, Evers, R, Nieves, E, et al. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci U S A. 2012;109(2):564–9.Google Scholar

Landfried, K, Zhu, W, Waldhier, MC, Schulz, U, Ammer, J, Holler, B, et al. Tryptophan catabolism is associated with acute GvHD after human allogeneic stem cell transplantation and indicates activation of indoleamine 2,3-dioxygenase. Blood. 2011;118(26):6971–4.Google Scholar

Elmaagacli, AH, Ditschkowski, M, Steckel, NK, Gromke, T, Ottinger, H, Hillen, U, et al. Human chorionic gonadotropin and indolamine 2,3-dioxygenase in patients with GvHD. Bone Marrow Transplant. 2014;49(6):800–5.Google Scholar

Holler, E, Butzhammer, P, Schmid, K, Hundsrucker, C, Koestler, J, Peter, K, et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20(5):640–5.Google Scholar

Jenq, RR, Ubeda, C, Taur, Y, Menezes, CC, Khanin, R, Dudakov, JA, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med. 2012;209(5):903–11.Google Scholar

Eriguchi, Y, Takashima, S, Oka, H, Shimoji, S, Nakamura, K, Uryu, H, et al. Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-defensins. Blood. 2012;120(1):223–31.Google Scholar

Munneke, JM, Björklund, AT, Mjösberg, JM, Garming-Legert, K, Bernink, JH, Blom, B, et al. Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. Blood. 2014;124(5):812–21.Google Scholar

Hanash, AM, Dudakov, JA, Hua, G, O’Connor, MH, Young, LF, Singer, NV, et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity. 2012;37(2):339–50.Google Scholar

Spoerl, S, Mathew, NR, Bscheider, M, Schmitt-Graeff, A, Chen, S, Mueller, T, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014;123(24):3832–42.Google Scholar

Pai, CC, Hsiao, HH, Sun, K, Chen, M, Hagino, T, Tellez, J, et al. Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels. Biol Blood Marrow Transplant. 2014 Jul 23. pii: S1083-8791(14)00448-0. doi: 10.1016/j.bbmt.2014.07.022. [Epub ahead of print]Google Scholar

Castilla-Llorente, C, Martin, PJ, McDonald, GB, Storer, BE, Appelbaum, FR, Deeg, HJ, et al. Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2014;49(7):966–71.Google Scholar

Ayuk, F, Bussmann, L, Zabelina, T, Veit, R, Alchalby, H, Wolschke, C, et al. Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation. Ann Hematol. 2014;93(5):855–61.Google Scholar

MacMillan, ML, DeFor, TE, Weisdorf, DJ. What predicts high risk acute graft-versus-host disease (GvHD) at onset?: identification of those at highest risk by a novel acute GvHD risk score. Br J Haematol. 2012;157(6):732–41.CrossRefGoogle ScholarPubMed

Weissinger, EM, Metzger, J, Dobbelstein, C, Wolff, D, Schleuning, M, Kuzmina, Z, et al. Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation. Leukemia. 2014;28(4):842–52.Google Scholar

Ferrara, JL, Harris, AC, Greenson, JK, Braun, TM, Holler, E, Teshima, T, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011;118(25):6702–8.Google Scholar

Vander Lugt, MT, Braun, TM, Hanash, S, Ritz, J, Ho, VT, Antin, JH, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013;369(6):529–39.Google Scholar

Gisselbrecht, C, Prentice, HG, Bacigalupo, A, Biron, P, Milpied, N, Rubie, H, et al. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 1994;343(8899):696–700.Google Scholar

Stahel, RA, Jost, LM, Cerny, T, Pichert, G, Honegger, H, Tobler, A, et al. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 1994;12(9):1931–8.Google Scholar

Klumpp, TR, Mangan, KF, Goldberg, SL, Pearlman, ES, Macdonald, JS. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995;13(6):1323–7.Google Scholar

Schmitz, N, Dreger, P, Zander, AR, Ehninger, G, Wandt, H, Fauser, AA, et al. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995;15(2):261–6.Google Scholar

Linch, DC, Milligan, DW, Winfield, DA, Kelsey, SM, Johnson, SA, Littlewood, TJ, et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol 1997;99(4):933–8.Google Scholar

Faucher, C, Le Corroller, AG, Chabannon, C, Novakovitch, G, Manonni, P, Moatti, JP, et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study. Bone Marrow Transplant 1996;17(4):533–6.Google Scholar

Bolwell, BJ, Pohlman, B, Andresen, S, Kalaycio, M, Goormastic, M, Wise, K, et al. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transplant 1998;21(4):369–73.Google Scholar

Bence-Bruckler, I, Bredeson, C, Atkins, H, McDiarmid, S, Hamelin, L, Hopkins, H, et al. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant 1998;22(10):965–9.Google Scholar

Piccirillo, N, Sica, S, Laurenti, L, Chiusolo, P, La Barbera, EO, Sora, F, et al. Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1999;23(12):1245–50.Google Scholar

Martino, M, Pratico, G, Messina, G, Irrera, G, Massara, E, Messina, G, et al. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol 2006;77(5):410–5.Google Scholar

Rifkin, R, Spitzer, G, Orloff, G, Mandanas, R, McGaughey, D, Zhan, F, et al. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010;10(3):186–91.Google Scholar

Gerds, A, Fox-Geiman, M, Dawravoo, K, Rodriguez, T, Toor, A, Smith, S, et al. Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2010;16(5):678–85.Google Scholar

Sebban, C, Lefranc, A, Perrier, L, Moreau, P, Espinouse, D, Schmidt, A, et al. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study). Eur J Cancer 2012;48(5):713–20.Google Scholar

Schriber, JR, Chao, NJ, Long, GD, Negrin, RS, Tierney, DK, Kusnierz-Glaz, C, et al. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Blood 1994;84(5):1680–4.Google Scholar

Locatelli, F, Pession, A, Zecca, M, Bonetti, F, Prete, L, Carra, AM, et al. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia. Bone Marrow Transplant 1996;17(1):31–7.Google Scholar

Hagglund, H, Ringden, O, Oman, S, Remberger, M, Carlens, S, Mattsson, J. A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplant 1999;24(8):831–6.Google Scholar

Bishop, MR, Tarantolo, SR, Geller, RB, Lynch, JC, Bierman, PJ, Pavletic, ZS, et al. A randomized, double-blind trial of filgrastim (granulocyte colony- stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000;96(1):80–5.Google Scholar

Przepiorka, D, Smith, TL, Folloder, J, Anderlini, P, Chan, KW, Korbling, M, et al. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 2001;97(11):3405–10.Google Scholar

Ciernik, IF, Schanz, U, Gmur, J. Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial. Bone Marrow Transplant 1999;24(2):147–51.Google Scholar

Schwab, L, Goroncy, L, Palaniyandi, S, Gautam, S, Triantafyllopoulou, A, Mocsai, A, et al. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. Nat Med 2014;20(6):648–54.Google Scholar

Ringden, O, Labopin, M, Gorin, NC, Le Blanc, K, Rocha, V, Gluckman, E, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004;22(3):416–23.Google Scholar

Ringden, O, Labopin, M, Gorin, NC, Volin, L, Torelli, GF, Attal, M, et al. Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic bone marrow transplantation. Br J Haematol 2012;157(2):220–9.Google Scholar

Volpi, I, Perruccio, K, Tosti, A, Capanni, M, et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood 2001;97(8):2514–21.Google Scholar

Dekker, A, Bulley, S, Beyene, J, Dupuis, LL, Doyle, JJ, Sung, L. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006;24(33):5207–15.Google Scholar

Vannucchi, AM, Bosi, A, Ieri, A, Guidi, S, Saccardi, R, Lombardini, L, et al. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial. Bone Marrow Transplant 1996;17(4):527–31.Google Scholar

Chao, NJ, Schriber, JR, Long, GD, Negrin, RS, Catolico, M, Brown, BW, et al. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin’s and non-Hodgkin’s lymphoma undergoing autologous bone marrow transplantation. Blood 1994;83(10):2823–8.Google Scholar

Ballen, KK, Becker, PS, Yeap, BY, Matthews, B, Henry, DH, Ford, PA. Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol 2004;22(20):4087–94.Google Scholar

Klaesson, S, Ringden, O, Ljungman, P, Lonnqvist, B, Wennberg, L. Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high- dose erythropoietin. Bone Marrow Transplant 1994;13(4):397–402.Google Scholar

Link, H, Boogaerts, MA, Fauser, AA, Slavin, S, Reiffers, J, Gorin, NC, et al. A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 1994;84(10):3327–35.Google Scholar

Biggs, JC, Atkinson, KA, Booker, V, Concannon, A, Dart, GW, Dodds, A, et al. Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian Bone Marrow Transplant Study Group. Bone Marrow Transplant 1995;15(1):129–34.Google Scholar

Paltiel, O, Cournoyer, D, Rybka, W. Pure red cell aplasia following ABO-incompatible bone marrow transplantation: response to erythropoietin. Transfusion 1993;33(5):418–21.Google Scholar

Fujisawa, S, Maruta, A, Sakai, R, Taguchi, J, Tomita, N, Ogawa, K, et al. Pure red cell aplasia after major ABO-incompatible bone marrow transplantation: two case reports of treatment with recombinant human erythropoietin. Transpl Int 1996;9(5):506–8.CrossRefGoogle ScholarPubMed

Gaya, A, Urbano-Ispizua, A, Fernandez-Aviles, F, Salamero, O, Roncero, JM, Rovira, M, et al. Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment. Biol Blood Marrow Transplant 2008;14(8):880–7.Google Scholar

Jaspers, A, Baron, F, Willems, E, et al. Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective, randomized trial. Blood. 2014;124(1):33–41.Google Scholar

Bolwell, B, Vredenburgh, J, Overmoyer, B, Gilbert, C, Chap, L, Menchaca, DM, et al. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant 2000;26(2):141–5.Google Scholar

Cheng, G, Saleh, MN, Marcher, C, Vasey, S, Mayer, B, Aivado, M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011;377(9763):393–402.Google Scholar

Molineux, G, Newland, A. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br J Haematol 2010;150(1):9–20.Google Scholar

Kuter, DJ. New thrombopoietic growth factors. Blood 2007;109(11):4607–16.Google Scholar

Ruiz-Delgado, GJ, Lutz-Presno, J, Ruiz-Arguelles, GJ. Romiplostin may revert the thrombocytopenia in graft-versus-host disease. Hematology 2011;16(2):108–9.Google Scholar

Reid, R, Bennett, JM, Becker, M, Chen, Y, Milner, L, Phillips, GL, et al. Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia. Am J Hematol 2012;87(7):743–5.Google Scholar

Liesveld, JL, Phillips, GL, Becker, M, Constine, LS, Friedberg, J, Andolina, JR, et al. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation. Biol Blood Marrow Transplant 2013;19(12):1745–52.Google Scholar

Goldman, J, Liesveld, J, Nichols, D, et al. ABO incompatibility between donor and recipient and clinical outcomes in allogeneic stem cell transplantation. Leuk Res 2003; 27:489–91.Google Scholar

Remberger, M, Watz, E, Ringden, O, Mattsson, J, Shjanwell, A, Wikman, A. Major ABO blood group mismatch increases the risk for graft failure after, unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13(6):675–82.Google Scholar

Buckner, CD, Clift, RA, Sanders, JE, et al. ABO-incompatible marrow transplants. Transplantation 1978; 26:233–8.Google Scholar

Warkentin, Pl, Yomtovian, R, Hurd, D, et al. Severe delayed hemolytic transfusion reaction complicating an ABO-incompatible bone marrow transplantation. Vox Sang 1983; 45:40–7.Google Scholar

Klummp, TR, Herman, JH, Ulicny, J, et al. Lack of effect of donor-recipient ABO mismatching outcome following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38:615–20.Google Scholar

Curley, C, Pillai, E, Mudie, K, et al. Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secreter plasma with or without plasma exchange. Transfusion 2012; 52:291–7.Google Scholar

Robeck, JD, Grossman, BJ, Harris, T, Hillyer, CD. Technical manual. Bethesda, MD: AABB; 2011.Google Scholar

Bender, JG, Bikto, L, Williams, S, et al. Defining a therapy dose of peripheral blood stem cells. J Hematother 1992; 1:329–41.Google Scholar

Rowley, SD. Hematopoietic stem cell transplantation between red cell incompatible donor-recipient pairs. Bone Marrow Transplant 2001; 28(4):315–21.Google Scholar

Cohn, C, Gaensler, K, Nambiar, A. Engraftment associated complications: Is it an allo-or an autoantibody? Transfusion 2010; 50(2S).Google Scholar

Akel, S, Regan, D, Petz, L, McCullough, J. Current thawing and infusion practice of cryopreserved cord blood: the impact on graft quality, recipient safety, and transplantation outcomes. Transfusion 2014; 54(11):2997–3009.Google Scholar

Stroncek, DF, Fautsch, SK, Lasky, LC, Hurd, DD, Ramsay, NKC, McCullough, J. Adverse reactions in patients transfused with cryopreserved marrow. Transfusion 1991; 31:521–7.Google Scholar

Malfuson, JV, Amor, RB, Bonin, P, Rodet, M, Boccaccio, C, Pautas, C, et al. Impact of nonmyeloablative conditioning regimens on the occurrence of pure red cell aplasia after ABO-incompatible allogeneic haematopoietic stem cell transplantation. Vax Sang 2007; 92(1):85–9.Google Scholar

Petz, LD. Immune hemolysis associated with transplantation. Semin Hematol 2005; 42(3):145–55.Google Scholar

Fleur, MA, Lichtiger, B, Bassett, R, et al. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietc cell transplantation. Br J Haematol 2013; 160:798–805.Google Scholar

Yazar, MH, Triulzi, DJ. Immune hemolysis following ABO-mismatched stem cell or solid organ transplantation. Curr Opin Hematol 2007; 14:664–70.Google Scholar

Karafin, MS, Blagg, L, Tobian, AA, et al. ABO antibody titers are not predictive of hemolytic reactions due to plasma-incompatible platelet transfusions. Transfusion 2012; 52:2087–93.Google Scholar

Mollison, P, Engelfriet, C, Contreras, M, editors. ABO, lewis and P groups and l antigens. 10th ed. Oxford, UK: Blackwell Science; 1997.Google Scholar

Petz, LO. Hemolysis associated with transplantation. Transfusion 1998; 38:224–8.Google Scholar

Bolan, CD, Childs, RW, Proter, JL, et al. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. Br J Haematol 2001; 112:787–95.Google Scholar

Daniel-Johnson, J, Schwartz, J. How do I approach ABO-incompatible hematopoietic progenitor cell transplantation? Transfusion 2011; 51:1143–9.Google Scholar

Gajewski, JL, Johnson, VV, Sandler, SG, et al. A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood 2008; 112:3036–47.Google Scholar

McCullough, J. Transfusion medicine. 3rd ed, Chapter 8. Oxford, UK: Wiley-Blackwell; 2012: 1–597.Google Scholar

Boctor, FN, Ali, NM, Mohandas, K, et al. Absence of D-alloimmunization in AIDS patients receiving D-mismatched RBCs. Transfusion 2003; 43:(2):173–6.Google Scholar

Ramsey, G, Hahn, LF, Cornell, FW, et al. Low rate of Rhesus immunization from Rh-incompatible blood transfusions during liver and heart transplant surgery. Transplantation 1989; 47(6):993–5.Google Scholar

Cummins, D, Contreras, M, Amin, S, et al. Red cell alloantibody development associated with heart and lung transplantation. Transplantation 1995; 59:1432–5.Google Scholar

Casanueva, M, Valdes, MD, Ribera, MC. Lack of alloimmunisation to D antigen in D-negative immunosuppressed liver transplant patients. Transfusion 1994; 34:570–2.Google Scholar

Menitove, JE. Immunoprophylaxis for D-patients receiving platelets from D+ donors? Transfusion 2002; 42:136–8.Google Scholar

Abou-Elells, AA, Camarillo, TA, Allen, BM, et al. Low incidence of red cell and HLA antibody formation by bone marrow transplant patients. Transfusion 1995; 35:931–5.Google Scholar

Parkman, R. Immunological reconstitution following bone marrow transplantation. In Bone marrow transplantation. Boston, MA: Blackwell Scientific; 1994; 504–12.Google Scholar

Atkinson, K. Reconstruction of the haemopoietic and immune systems after marrow transplantation. Bone Marrow Transplant 1990; 5(4):209–26.Google Scholar

Friedberg, RC. Transfusion therapy in the patient undergoing hematopoietic stem cell transplantation. Hematol Oncol Clin North Am 1994; 8(6):1105–16. Review.Google Scholar

Heddle, NM, Soutar, RL, O’Hoski, PL, et al. A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion. Br J Haematol 1995; 91(4):1000–5.Google Scholar

Azuma, E, Nishihara, H, Hanada, M. Recurrent cold hemagglutinin disease following allogeneic bone marrow transplantation successfully treated with plasmapheresis, corticosteroid and cyclophosphamide. Bone Marrow Transplant 1996; 18(1):243–6.Google Scholar

Wennerberg, A, Backman, KA, Gillerlain, C. Mixed erythrocyte chimerism: implications for tolerance of the donor immune system to recipient non-ABO system red cell antigens. Bone Marrow Transplant 1996; 18(2):433–5.Google Scholar

Sachs, V. Immune haemolysis after organ transplantation. Transf Med 1995; 5(1):87.Google Scholar

Chen, F, Owen, I, Savage, D, et al. Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant. Bone Marrow Transplant 1997; 19:491–5.Google Scholar

Drobyski, WR, Potluri, J, Sauer, D, Gottschall, JL. Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 17(6):1093–9.Google Scholar

Horn, B, Viele, M, Mentzer, W, et al. Autoimmune hemolytic anemia in patients with SCID after T cell-depleted BM and PBSC transplantation. Bone Marrow Transplant 1999; 24(9):1009–13.Google Scholar

Mijovic, A. Alloimmunization to RhD antigen in RhD-incompatible haemopoietic cell transplants with non-myeloablative conditioning. Vox Sang 2002; 83:358–362.Google Scholar

Erker, CG, Steins, MB, Fischer, RJ, et al. The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation. Transfusion 2005; 45:1382–90.Google Scholar

Wirk, B, Klumpp, TR, Ulicny, J, et al. Lack of effect of donor-recipient Rh mismatch on outcomes after allogeneic hematopoietic stem cell transplantation. Transfusion 2008; 48:163–8.Google Scholar

Berkman, EM, Caplan, SN. Engraftment of RH-positive marrow in a recipient with RH antibody. Transplant Proc 1977; 9(1 Suppl 1):215–8.Google Scholar

Rigal, D, Monestier, M, Meyer, F, Tremisi, PJ, et al. Transplant of rhesus-positive bone marrow in a rhesus-negative woman having anti-rhesus D alloantibodies. Acta Haematol 1985; 73(3):153–6.Google Scholar

Taylor, PA, Ehrhardt, MJ, Roforth, MM, et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood 2007; 109:1307–15.Google Scholar

Warkentin, PI, Hilden, JM, Kersey, JH, et al. Transplantation of major ABO-incompatible bone marrow depleted of red cells by hydroxyethyl starch. Vox Sang 1985; 48(2):89–104.Google Scholar

Kalacioglu, M, Copelan, E, Avalos, B, et al. Survival after ABO-incompatible allogeneic bone marrow transplant after a preparative regimen of busulfan and cyclophosphamide. Bone Marrow Transplant 1995; 15:105–10.Google Scholar

Booth, GS, Gerhie, EA, Bolan, CD, Savani, BN. Clinical guide to ABO-incompatible allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19:1152–8Google Scholar

Lichtiger, B, Hester, JP. Transfusion of Rh-incompatible blood components to cancer patients. Haematologia 1986; 19:81–8.Google Scholar

Asfour, M, Narvios, A, Lichtiger, B. Transfusion of RhD-incompatible blood components in RhD-negative blood marrow transplant recipients. Med Gen Med 2004; 13:22.Google Scholar

Goldfinger, D, MGinniss, MH. Rh-incompatible platelet transfusion: risks and consequences of sensitizing immunosuppressed patients. N Engl J Med 1971; 284:942.Google Scholar

McLeod, BC, Piehl, MR, Sassetti, RJ. Alloimmunizaation to RhD by platelet transfusion in autologous bone marrow transplant recipients. Vox Sang 1990; 59:185–9.Google Scholar

Avache, S, Herman, JH. Prevention of D sensitization after mismatched transfusion of blood components: toward optimal use of RhIG. Transfusion 2008; 48:1990–9.Google Scholar

Pfisterer, H, Thierfelder, S, Kottusch, H, et al. Examination of human thrombocytes for Rhesus antigens using decomposition studies in vivo following Cr 51 labelling. Klin Wochenschr 1967; 45(10):519–22.Google Scholar

Burnie, KM, Barr, RM. Unpublished observations cited by Mollsion, PL, Engelfriet, CP, Contreras, M. In Blood transfusion in clinical medicine, 9th edition. Oxford: Blackwell; 1993: 235.Google Scholar

McBride, JA, O’Hoski, P, Blasjchman, MA, et al. Rhesus alloimmunisation following intensive plasmapheresis. Transfusion 1978; 18:626–7.Google Scholar

O’Shaughnessy, DF, Atterbury, C, Bolton Maggs, P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. British Committee for Standards in Haematology, Blood Transfusion Task Force. Br J Haematol 2004; 126(1):11–28.Google Scholar

Barclay, GR, Greiss, MA, Urbaniak, SJ. Adverse effect of plasma exchange on anti-D production in rhesus immunization owing to removal of inhibitory factors. BMJ 1980; 280(6231):1569–71.Google Scholar

Schorr, JB, Schorr, PT, Francis, R, et al. The antigenicity of C and E antigens when transfused into Rh-negative (rr) and Rh-positive recipients. Chicago, IL: Commun Am Assoc Blood Banks; 1971.Google Scholar

Huestis, DW. International forum: what constitutes adequate routine Rh typing on donors and recipients? Vox Sang 1971; 21:183.Google Scholar

Leo, A, Mytilineos, J, Voso, MT, et al. Passenger lymphocyte syndrome with severe hemolytic anemia due to an anti-Jk(a) after allogeneic PBPC transplantation. Transfusion 2000; 40(6):632–6.Google Scholar

Ting, A, Pun, A, Dodds, AJ, Atkinson, K, et al. Red cell alloantibodies produced after bone marrow transplantation. Red cell alloantibodies produced after bone marrow transplantation. Transfusion 1987; 27(2):145–7.Google Scholar

de la Rubia, J, Arriaga, F, Andreu, R, et al. Development of non-ABO RBC alloantibodies in patients undergoing allogeneic HPC transplantation. Is ABO incompatibility a predisposing factor? Transfusion 2001; 41:106–10.Google Scholar

Zupańska, B, Zaucha, JM, Michalewska, B, et al. Multiple red cell alloantibodies, including anti-Dib, after allogeneic ABO-matched peripheral blood progenitor cell transplantation. Transfusion 2005; 45(1):16–20.Google Scholar

López, A, de la Rubia, J, Arriaga, F, et al. Severe hemolytic anemia due to multiple red cell alloantibodies after an ABO-incompatible allogeneic bone marrow transplant. Transfusion 1998; 38(3):247–51.Google Scholar

Dinsmore, RE, Reich, LM, Kapoor, N, et al. ABH incompatible bone marrow transplantation: removal of erythrocytes by starch sedimentation. Br J Haematol 1983; 54(3):441–9.Google Scholar

Lasky, LC, Warkentin, PI, Kersey, JH, et al. Hemotherapy in patients undergoing blood group incompatible bone marrow transplantation. Transfusion 1983; 23(4):277–85.Google Scholar